Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
TuHURA Reports Partial Responses in First Three Patients in IFx-2.0–Keytruda Merkel Cell Carcinoma Trial

TuHURA Reports Partial Responses in First Three Patients in IFx-2.0–Keytruda Merkel Cell Carcinoma Trial

BitgetBitget2026/10/26 11:31
  • TuHURA Biosciences on October 26, 2026, reported preliminary results from its Phase 1b/2a trial of IFx-2.0 with Keytruda for metastatic Merkel cell carcinoma.
  • All three initial patients experienced substantial tumor shrinkage, with responses ongoing at six months.
  • The nine-patient study evaluates safety and feasibility in patients with deep-seated or bulky tumors receiving first-line treatment.
  • Continued strong responses could prompt trial expansion and FDA discussions about supplementing the ongoing Phase 3 trial, contingent on its success.
  • Results have been disclosed; presentation at a scientific conference is planned for 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610260730PR_NEWS_USPR_____LA80464) on October 26, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Investors reportedly offering Anthropic allocation shares at premiums of up to 5% ahead of its IPO

According to reports, the trading firm JonesTrading is marketing up to $500 million worth of stock shares on behalf of some investors, at a 3% to 5% premium over the IPO issue price. This indicates that investors are already transferring their anticipated IPO allotted shares before the IPO is officially issued.

华尔街见闻•2026/11/10 23:03